RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Newsroom

Christopher Knight joins RTI Health Solutions, adding decision analysis expertise

RESEARCH TRIANGLE PARK, NC — Christopher Knight has returned as a Senior Director of Health Economics to RTI Health Solutions, a business unit of RTI International.

Knight, an expert in operational research, has formal training in decision analysis and extensive experience in using these and other statistical modeling techniques to develop analyses to support the reimbursement of pharmaceuticals and other healthcare technologies.

He has over 20 years of experience in developing mathematical models to support planning the UK's National Health Service (NHS) resources and developing health economic models to evaluate the cost-effectiveness and budget impact of new treatments across a wide range of therapy areas.  He has led multiple teams on projects for the UK's National Institute for Health and Care Excellence (NICE) and NHS. He  has developed economic models to support decision making at all points of the product life cycle, from early in the product development to inform strategic decisions and research planning, through to models for Health Technology Assessment (HTA) submissions and publication.  

Prior to joining RTI Health Solutions, Knight worked as Director of Cost-Effectiveness Modelling with BresMed Health Solutions and as a Senior Analyst at both University of Sheffield and Trent Regional Health Authority.

"We are so pleased to welcome Chris back to RTI Health Solutions," said Sorrel Wolowacz, Head of European Health Economics at RTI-HS. "In his new role, Chris enhances our ability to support our clients in developing economic models. His modeling experience combined with his knowledge of various reimbursement systems and background of having worked for a national agency and in consulting supporting pharmaceutical manufacturers will help us better advise clients on potential questions and pitfalls associated with HTA submissions."

One of Knight's research interests is performing economic analyses for new treatments for orphan diseases. He has developed economic models for drugs to treat osteosarcoma, mucopolysaccharidosis, and Castleman's disease, and he has an extensive background in leading economic analyses for haemophilia treatments.

Knight holds a bachelor's degree in mathematics, statistics and computing from De Montfort University in Leicester, UK, and a master's of science in operational research from the University of Birmingham.

He is a member of the International Society for Pharmacoeconomics and Outcomes Research. His research on health economics has been published in peer-reviewed journals, and he serves as a peer reviewer for European Journal of Health Economics, Medical Decision Making, Pharmacoeconomics, Clinical Therapeutics, and Haemophilia.